EMA recommends marketing authorization for donanemab (Kisunla)
This announcement reverses an earlier recommendation made by the EMA regarding donanemab as a treatment for the treatment of early symptomatic Alzheimer's disease in adults.
News
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Featured news
The 78th World Health Assembly agrees to extend the Global Action Plan on the Public Health Response to Dementia
The 78th World Health Assembly has been a whirlwind week for ADI as, after 18-months of advocacy, the World Health Assembly has agreed to extend the Global Action Plan on the Public Health Response to Dementia by 6-years, to 2031.
Strengthening Dementia Advocacy in Mexico: ADI Advances Strategic Partnerships for National Implementation
As part of ADI's ongoing regional commitment to dementia policy, Diego Aguilar, Regional Director for the Americas, completed a high-impact country visit to Mexico that combined academic engagement, civil society coordination, and high-level government and industry dialogue.
Asia Pacific Spotlight: High-level meeting in Hanoi and Lyon
This month, ADI’s Regional Director for the Asia Pacific, DY Suharya, partook in a number of important meetings and events both in Lyon, France at the WHO Academy, and in Hanoi, Vietnam, alongside Vietnam International Organisation for Better Ageing (VIOBA), who are currently partaking in ADI’s Membership Development Programme.
Scottish Medicines Consortium upholds decision not to recommend lecanemab
This announcement reaffirms the Scottish Medicines Consortium’s decision of 10 February 2025, meaning that no disease-modifying therapies for Alzheimer’s disease are currently approved for use in Scotland.
Civil Society and Lawmakers Push Forward Argentina’s National Alzheimer Law in San Juan
In June, ADI’s Regional Director for the Americas, Diego Aguilar, attended a national meeting of Alzheimer’s associations in San Juan, Argentina. The meeting sought to unite lawmakers, civil society, healthcare professionals and more from across Argentina in an effort to call for legislation surrounding Alzheimer’s under the banner of #LeyAlzheimerYa (#AlzheimersLawNow).
Revisiting the World Alzheimer Report 2024: Challenging dementia stigma in popular culture & why we need media guidelines
Perceptions of dementia are dependent on many factors, such as direct personal experience with a loved one having the condition or exposure to public information campaigns, for example. Popular culture also plays a role in shaping the public discourse around dementia in ways that can have significant consequences on the…
UK National Health Service to deny free Alzheimer’s treatments
The National Institute for Health and Care Excellence (NICE) has concluded that the benefits from two treatments for early Alzheimer's Disease, donanemab and lecanemab, remain too small to justify the additional cost. Consequently, free access to these Alzheimer's treatments will not be provided in the UK.
Revisiting the World Alzheimer Report 2024: Becoming an advocate and a force for change as an LGBTQ+ person with early-onset dementia
Challenging dementia stigma is one of ADI’s core missions, and one where there is unfortunately still a long way to go. ADI’s global survey on attitudes to dementia in 2024 revealed that a worrying 80% of the general public still thinks that dementia is a normal part of ageing,…
Spotlight on Asia Pacific: Research, Advocacy and Awards
In May, ADI’s Regional Director for the Asia Pacific Region, DY Suharya travelled to Sydney, Australia to participate in the launch of the e-DiVA programme alongside representatives from Australia, New Zealand, Indonesia, and Viet Nam. Then, ADI Board Member and Executive Vice President of ADI member Alzheimer’s Disease Chinese, Professor Huali Wang, was one of the six public health champions celebrated at the 78th World Health Assembly later in the month.